Associate Professor of Oncology, Johns Hopkins University School of Medicine; Interim director, Sidney Kimmel Comprehensive Cancer Center (Johns Hopkins Bayview campus), Interim Co-Director, Upper Aerodigestive Program
Oncology
Dr. Julie R. Brahmer, MD
|
|
Give Review
Doctor Julie R. Brahmer, MD is an expert in the field of Oncology. She went to University of Nebraska College of Medicine. She has 2 awards "CMS Meaningful Use Stage 1 Certification" and "Fellow (FASCO)". Julie Brahmer is also a published physician. She has 79 paper published. The most recent paper is: Nivolumab: targeting PD-1 to bolster antitumor immunity. She accepts Medicare payments and is registered with Medicare.gov.
Publications
- Clinical Outcomes in Elderly Patients with Advanced Non-small Cell Lung Cancer: Results from ARIES, a Bevacizumab Observational Cohort Study.
- Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non-Small Cell Lung Cancer.
- Nivolumab: targeting PD-1 to bolster antitumor immunity.
- Safety and Effectiveness of Bevacizumab-Containing Treatment for Non-Small-Cell Lung Cancer: Final Results of the ARIES Observational Cohort Study.
- Reply: Regulatory T cells-an important target for Cancer immunotherapy.
- Five National Cancer Institute-designated Cancer centers' data collection on racial/ethnic minority participation in therapeutic trials: A current view and opportuniti...
- New Strategies in Lung Cancer: Epigenetic Therapy for Non-Small Cell Lung Cancer.
- Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new antiCancer strategy.
- Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report.
- New strategies in lung Cancer: translating immunotherapy into clinical practice.
- Breathing new life into immunotherapy: review of melanoma, lung and kidney Cancer.
- Dosing to rash: A phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung Cancer an Eastern Cooperative Oncology Group Study (E3503).
- Alterations of immune response of non-small cell lung Cancer with Azacytidine.
- A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non...
- Body Mass Index and Its Association with Clinical Outcomes for Advanced Non-Small-Cell Lung Cancer Patients Enrolled on Eastern Cooperative Oncology Group Clinical Tri...
- Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung Cancer.
- Baseline tumour measurements predict survival in advanced non-small cell lung Cancer.
- A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours.
- Targeting the Immune System in the Treatment of Non-Small-Cell Lung Cancer.
- Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung Cancer.
- A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non-Small Cell Lung Cancer.
- Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung Cancer.
- Harnessing the immune system for the treatment of non-small-cell lung Cancer.
- Durable Cancer Regression Off-Treatment and Effective ReinDuction Therapy with an Anti-PD-1 Antibody.
- PD-1-Targeted Immunotherapy: Recent Clinical Findings.
- Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors.
- Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung Cancer treated with or without bevacizumab in combina...
- Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid Tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
- Clinical course of advanced non-small-cell lung Cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclita...
- Inhibition of the hedgehog pathway in advanced basal-cell Carcinoma.
- Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid Malignancies.
- Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung Cancer.
- Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung Cancer.
- Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
- Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung Cancer.
- Chemotherapy for advanced stage non-small cell lung Cancer.
- "Who should receive epidermal growth factor receptor inhibitors for non-small cell lung Cancer and when?".
- Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced Cancer.
- Delayed diagnosis and elevated mortality in an urban population with HIV and lung Cancer: implications for patient care.
- Second-line Therapy for advanced non-small-cell lung Cancer.
- Adjuvant treatment in non-small cell lung Cancer: Where are we now?
- Adjuvant therapy for resected non-small-cell lung Cancer: past, present, and future.
- Adjuvant therapy for resected non-small-cell lung Cancer: recent advances, emerging agents, and lingering questions.
- Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.
- Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile.
- Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry.
- What lies within: novel strategies in immunotherapy for non-small cell lung Cancer.
- Concordance of Cancer patients'' function, symptoms, and supportive care needs.
- Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung Cancer.
- Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30.
- Symptoms, supportive care needs, and function in Cancer patients: how are they related?
- Outcomes for elderly, advanced-stage non small-cell lung Cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern C...
- ASking the right questions: investigating needs assessments and health-related quality-of-life questionnaires for use in oncology clinical practice.
- Non-small cell lung Cancer: adjuvant and neo-adjuvant chemotherapy.
- Mass spectrometry to classify non-small-cell lung Cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors...
- Targeting the epidermal growth factor receptor in non-small-cell lung Cancer: who, which, when, and how?
- Pleural mesothelioma metastatic to tongue.
- Phase II trial of gemcitabine/carboplatin followed by paclitaxel in patients with performance status=2,3 or other significant co-morbidity (HIV infection or s/p organ ...
- Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid Tumors.
- Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung Cancer.
- Clinical Cancer Advances 2009: major research advances in Cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
- American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung Cancer.
- Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung Cancer in Eastern Cooperative Oncol...
- Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell ...
- Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung Cancer treated with erlotinib-containing regimen.
- Imaging delta- and mu-opioid receptors by PET in lung Carcinoma patients.
- Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in Cancer patients.
- Gemcitabine and vinorelbine in recurrent advanced non-small cell lung Cancer: sequence does matter.
- Pathology quiz case 1. Metastatic mesothelioma involving the tongue.
- CYP3A phenotyping approach to predict Systemic exposure to EGFR tyrosine kinase inhibitors.
- Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung Cancer.
- C-fos assessment as a marker of anti-epidermal growth factor receptor effect.
- Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in Cancer patients.
- Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung Cancer.
- Surgical resection of limited disease small cell lung Cancer in the new era of platinum chemotherapy: Its time has come.
- Management of Malignant pleural effusion.
- [American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung Cancer].
- Emerging treatments for choroidal metastases.
Schools
University of Nebraska College of Medicine
Johns Hopkins University School Med
University Of Ut Med Center
Conditions Treated
- Anemia
- Bile Duct Cancer
- Bladder Cancer
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Fellow (FASCO)
Education
-
Johns Hopkins University -
University of Utah -
University of Nebraska College of Medicine
Hospital
-
Johns Hopkins Bayview Medical Center -
Johns Hopkins Hospital
Drug Facts
| NPI NUMBER | 1982661989 | |
| NPPES Provider LastName | BRAHMER | |
| NPPES Provider FirstName | JULIE | |
| NPPES Provider ZIPCode | 212870005 | |
| NPPES Provider State | MD | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 148.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1982661989 |
| Last Name Of The Provider | BRAHMER |
| First Name Of The Provider | JULIE |
| View All |
Similar Doctors
|
|
Dr. John H. Fetting III, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mayer M. Gorbaty, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Georgia B. Vogelsang, MD |
|
|
Dr. Judy Hetherington, MD |
|
|
Dr. Seamus Oreilly, MD |